Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.

Trial Details

NCT ID
NCT07192432
Phase
PHASE1 / PHASE2
Sponsor
Vironexis Biotherapeutics Inc.
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Dose Level 1, VNX-202
  • Dose Level 2, VNX-202
  • Dose Level 3, VNX-202
  • Dose Level 4, VNX-202
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Denver, Colorado, United States|39.73915,-104.9847
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Age: ≥18 years of age
  • Histologically or cytologically confirmed diagnosis of HER-2 positive solid tumor as defined in the protocol
  • Part 1: presence of advanced or metastatic disease that has progressed during or following previous treatment
  • Part 2: Early stage HER-2 positive cancers with high risk for relapse following completion of SOC or after neoadjuvant systemic treatment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →